Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CA5A | P35218 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10775549 | 0.78 | STAT3 (0.81) | STAT3CA1CA2CA9CA4 | |
| SCHEMBL10778903 | 0.76 | STAT3 (0.72) | STAT3CA1CA2CA9CA4 | |
| SCHEMBL1477522 | 0.73 | STAT3 (0.73) | STAT3CA1CA2CA9CA4 | |
| SCHEMBL17006271 | 0.73 | STAT3 (0.58) | STAT3CA1CA2CA9CA4 | |
| SCHEMBL29865019 | 0.73 | STAT3 (0.58) | STAT3CA1CA2CA9CA4 | |
| SCHEMBL30402468 | 0.73 | STAT3 (0.41) | STAT3CA1CA2CA9CA4 | |
| SCHEMBL8602406 | 0.72 | TYMS (0.49) | CA1CA2CA9CA7 | |
| SCHEMBL5793477 | 0.72 | MAOA (0.56) | STAT3CA1CA2CA9CA7 | |
| SCHEMBL12310760 | 0.70 | STAT3 (1.00) | STAT3CDK2 | |
| SCHEMBL22606378 | 0.70 | STAT3 (0.69) | STAT3CA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783513-B2 | STAT3 inhibitors and their anticancer use | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783513-B2 | STAT3 inhibitors and their anticancer use | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783513-B2 | STAT3 inhibitors and their anticancer use | OHIO STATE INNOVATION FOUNDATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150232434-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | OHIO STATE INNOVATION FOUNDATION | 2015-08-20 | — | — | US | disclosed |
| US-20150232434-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | OHIO STATE INNOVATION FOUNDATION | 2015-08-20 | — | — | US | disclosed |
| US-20150232434-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | OHIO STATE INNOVATION FOUNDATION | 2015-08-20 | — | — | US | disclosed |
| EP-2884971-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | Ohio State Innovation Foundation (US) | 2015-06-24 | — | — | EP | disclosed |
| WO-2014028909-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | OHIO STATE INNOVATION FOUNDATION (US) | 2014-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232434-A1 | STAT3 INHIBITORS AND THEIR ANTICANCER USE | STAT3, STAT1, JAK1 | STAT3 1/4885CA1 1668/4885CA2 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.